Seer, Inc. (NASDAQ: SEER) has entered into a partnership with Precision Health Research in Singapore to deploy its Proteograph® Product Suite for deep, unbiased plasma proteome profiling of 10,000 participants in the PRECISE‑SG100K cohort. The collaboration combines Seer’s nanoparticle‑enriched workflow with Thermo Fisher Scientific’s Olink® Reveal and Orbitrap Astral™ mass spectrometers to generate high‑resolution proteomic data for a multi‑ancestry Asian population study.
The PRECISE‑SG100K initiative is a landmark population‑scale project that has recruited over 100,000 Singapore residents and aims to integrate genomic, proteomic, and phenotypic data to advance precision health. By adding Seer’s Proteograph platform, the study will obtain thousands of quantified proteins with peptide‑level resolution, providing a mechanistic layer that links genetic variation to protein networks and clinical outcomes.
Seer’s technology validation in this high‑profile cohort is expected to drive new instrument placements and consumable pull‑through, supporting the company’s goal of accelerating adoption of its Proteograph ONE workflow. The ONE assay can process more than 1,000 samples per week, a tenfold increase over earlier versions, and the partnership positions Seer to capture a larger share of the growing population‑scale proteomics market.
Seer’s most recent financial results show a Q4 2025 revenue of $4.2 million, a 5% increase from $4.0 million in Q4 2024, but a miss against analyst expectations of $5.2 million. Full‑year 2025 revenue reached $16.6 million, up 17% from $14.2 million, while the company guided 2026 revenue to $16–18 million, reflecting a modest 3% growth outlook. CFO David Horn noted that the guidance reflects pressure on instrument placements and new project funding amid uncertainty around NIH funding.
CEO Omid Farokhzad highlighted that Seer’s Proteograph has been selected to power multiple population‑scale studies, underscoring the platform’s scalability and the company’s expanding installed base. The partnership with PRECISE‑SG100K further demonstrates Seer’s ability to deliver deep proteomic data at scale and reinforces its position as a leader in AI‑driven biological discovery.
The collaboration expands Seer’s reach into the rapidly growing Asian market and complements Thermo Fisher’s existing proteomics portfolio. By integrating Seer’s high‑throughput workflow with Thermo Fisher’s advanced mass spectrometry instruments, the partnership is poised to accelerate the generation of actionable proteomic insights for precision health research.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.